Sex, drugs and gender roles: Mapping the use of sex and gender based analysis in pharmaceutical policy research

International Journal for Equity in Health

Volumn 9, Issue , 2010, Pages

  Greyson, Devon L ^a   Becu, Annelies R E ^a   Morgan, Steven G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; GENDER ROLE; HEALTH POLICY; MAPPING; RESEARCH AND DEVELOPMENT; SEX ROLE; WOMENS HEALTH;

ARTICLE; DRUG RESEARCH; DRUG USE; HEALTH CARE POLICY; LANGUAGE; LAW; MEDICAL LITERATURE; MEDLINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEX DIFFERENCE;

EID: 78349282694     PISSN: None     EISSN: 14759276     Source Type: Journal    
DOI: 10.1186/1475-9276-9-26     Document Type: Article

References (42)

1. Institute of Gender and Health, Gender matters: IGH strategic plan 2009-2012 Ottawa, ON 2009
2. J Johnson L Greaves R Repta, Better science with sex and gender: a primer for health research Vancouver. BC: Women's Health Research Network of BC 2007
3. Health Canada, Exploring concepts of gender and health Ottawa, ON 2003 http://www.hc-sc.gc.ca/hl-vs/pubs/women-femmes/explor-eng.php
4. DL Spitzer, Gender and sex-based analysis in health research: A guide for CIHR researchers and reviewers Ottawa, ON 2007
5. C Fuller, Women and adverse drug reactions reporting in the Canadian context Toronto, ON: Women and Health Protection 2003 http://www.whp-apsf.ca/ pdf/fullerReport.pdf
6. The women's health movement in Canada: looking back and moving forward. M Boscoe G Basen G Alleyne B Bourrier-Lacroix S White, Canadian Woman Studies/les cahiers de la femme 2004 24 1 7 13
7. Boston Women's Health Book Collective J Norsigian, Our Bodies, Ourselves: A New Edition for a New Era New York, NY: Simon & Schuster 2005
8. AR Ford D Saibil, The push to prescribe: women & Canadian drug policy Toronto, ON: Women's Press/Canadian Scholars' Press 2009
9. A Lippman, The Inclusion of Women in Clinical Trials: Are We Asking the Right Questions? Toronto, ON: Women and Health Protection 2006
10. National Institutes of Health revitalization act of 1993. U.S. Congress, Washington, DC 1993 http://history.nih.gov/research/downloads/PL103-43.pdf
11. Health Canada, Therapeutic products programme guidelines: inclusion of women in clinical trials Ottawa, ON: Health Canada 1997 http://www.hc-sc.gc.ca/ dhp-mps/prodpharma/applic-demande/guide-ld/clini/womct-femec-eng.php
12. Canadian Institutes of Health Research, Gender and sex-based analysis in health research: a guide for CIHR researchers and reviewers Ottawa, ON: CIHR 2007 http://www.cihr-irsc.gc.ca/e/32019.html
13. World Health Organization, WHO gender mainstreaming strategy Geneva, Switzerland 2007 http://www.who.int/gender/mainstreaming/strategy/en/index.html
14. Scoping studies: towards a methodological framework. H Arksey L O'Malley, Int J of Soc Research Methodol 2005 8 1 19 32 10.1080/1364557032000119616 (Pubitemid 40322704)
15. What are scoping studies? A review of the nursing literature. K Davis N Drey D Gould, Int J Nurs Stud 2009 46 10 1386 1400 10.1016/j.ijnurstu.2009.02. 010 19328488
16. Asking the right questions: Scoping studies in the commissioning of research on the organisation and delivery of health services. S Anderson P Allen S Peckham N Goodwin, Health Res Policy Syst 2008 6 7 10.1186/1478-4505-6-7 18613961
17. Pharma Policy 101. Pharmaceutical Policy Research Collaboration, PharmaceuticalPolicy.ca Vancouver, BC: University of British Columbia 2010 http://www.pharmaceuticalpolicy.ca/pharma-policy-101
18. Introduction: Beyond gender matters. C Varcoe O Hankivsky M Morrow, Women's health in Canada: critical perspectives on theory and policy Toronto, ON: University of Toronto Press, Morrow M, Hankivsky O, Varcoe C, 2007 3 30
19. Over the counter medicines: proceed with caution. RE Ferner K Beard, BMJ 2008 336 7646 694 696 10.1136/bmj.39504.389676.AD 18369225
20. Pharmaceutical patent life-cycle management after KSR v. Teleflex.x. ME Furrow, Food Drug Law J 2008 63 1 275 320 18561462
21. Expanded access to Phase II clinical trials in oncology: a step toward increasing scientific validity and compassion. AK Marcee, Food Drug Law J 2008 63 2 439 457 18561471
22. Representation and legitimacy in health policy formulation at a national level: perspectives from a study of health technology eligibility procedures in the United Kingdom. T Milewa, Health Policy 2008 85 3 356 362 10.1016/j.healthpol.2007.09.001 17936401
23. Combating the "other diseases" of MDG 6: changing the paradigm to achieve equity and poverty reduction? DH Molyneux, Trans R Soc Trop Med Hyg 2008 102 6 509 519 10.1016/j.trstmh.2008.02.024 18413278
24. Patients' understanding of the regulation of dietary supplements. BH Ashar RG Miller CP Pichard R Levine SM Wright, J Community Health 2008 33 1 22 30 10.1007/s10900-007-9063-7 18080205
25. Impact of a Medicaid copayment policy on prescription drug and health services utilization in a fee-for-service Medicaid population. DM Hartung MJ Carlson DF Kraemer DG Haxby KL Ketchum MR Greenlick, Med Care 2008 46 6 565 572 10.1097/MLR.0b013e3181734a77 18520310
26. Medication use in the neonatal intensive care unit: current patterns and off-label use of parenteral medications. P Kumar JK Walker KM Hurt KM Bennett N Grosshans MA Fotis, J Pediatr 2008 152 3 412 415 10.1016/j.jpeds.2007.07.050 18280851
27. Effect of legislative changes in drug promotion on medical students: questionnaire survey. L Vuorenkoski M Valta O Helve, Med Educ 2008 42 12 1172 1177 10.1111/j.1365-2923.2008.03169.x 19120947
28. The treatment of adolescent transsexuals: changing insights. PT Cohen-Kettenis HA Delemarre-van de Waal LJ Gooren, J Sex Med 2008 5 8 1892 1897 10.1111/j.1743-6109.2008.00870.x 18564158
29. Medication abortion in Canada: a right-to-health perspective. JN Erdman A Grenon L Harrison-Wilson, Am J Public Health 2008 98 10 1764 1769 10.2105/AJPH.2008.134684 18703434
30. Clinical trials in Canada: whose interests are paramount? J Lexchin, Int J Health Serv 2008 38 3 525 542 10.2190/HS.38.3.h 18724580
31. Gender-based analysis and health policy: the need to rethink outdated strategies. O Hankivsky, Toronto, ON: University of Toronto Press, Morrow M, Hankivsky O, Varcoe C, 2007 143 168
32. A tool for developing gender research in medicine: Examples from the medical literature on work life. A Hammarström, Gender Med 2007 4 Suppl B 123 S132 10.1016/S1550-8579(07)80053-2
33. Assessment of analysis by gender in the Cochrane reviews as related to treatment of cardiovascular disease. SM Johnson CA Karvonen CL Phelps S Nader BC Sanborn, J Women's Health 2003 12 5 449 457 10.1089/154099903766651577
34. Appraising the evidence: Applying sex- and gender-based analysis (SGBA) to Cochrane systematic reviews on cardiovascular disease. MD Doull VE Runnels S Tudiver M Boscoe, J Women's Health 2010 19 5 997 1003 10.1089/jwh.2009.1626
35. No-fault compensation for medical injuries: the prospect for error prevention. DM Studdert TA Brennan, JAMA 2001 286 2 217 10.1001/jama.286.2.217 11448285
36. The Origins and development of the diffusion of innovations paradigm as an example of scientific growth. TW Valente EM Rrogers, Sci Commun 1995 16 3 242 273 10.1177/1075547095016003002 12319357
37. Trial Registration at ClinicalTrials.gov between May and October 2005. DA Zarin T Tse NC Ide, N Engl J Med 2005 353 26 2779 2787 10.1056/NEJMsa053234 16382064
38. The effect of evidence-based drug coverage policies on pharmaceutical R&D: a case study from British Columbia. S Morgan C Cunningham, Healthcare Policy 2008 3 3 1 25
39. Medicine by media: did a critical television documentary affect the prescribing of cyproterone-estradiol (Diane-35)? B Mintzes S Morgan KL Bassett, CMAJ 2005 173 11 1313 16301694
40. Cost-related prescription nonadherence in the United States and Canada: a system-level comparison using the 2007 international health policy survey in seven countries. J Kennedy S Morgan, Clin Ther 2009 31 1 213 219 10.1016/j.clinthera.2009.01.006 19243719
41. Patients at-risk for cost-related medication nonadherence: a review of the literature. BA Briesacher JH Gurwitz SB Soumerai, J Gen Intern Med 2007 22 6 864 871 10.1007/s11606-007-0180-x 17410403
42. Chronic catastrophes: exploring the concentration and sustained nature of ambulatory prescription drug expenditures in the population of British Columbia, Canada. GE Hanley S Morgan, Soc Sci Med 2009 68 5 919 924 10.1016/j.socscimed.2008.12.008 19135288